A new scientific publication is expected with Winclove Travel on protection against potential pathogens. The publication has been accepted by Gut Pathogens for publication and will soon be published. This new research has been carried out in collaboration with researchers from the University of Urbino Italy.
Traveller’s diarrhoea (TD) is an unpleasant problem that can disrupt holidays and business trips. It usually occurs when people travel to high-risk areas, where the chance of developing TD is around 40%, such as the Middle East, Southern and South-East Asia, South and Central America and the developing countries in Africa1,2. (See figure 1).
TD often starts 2-3 days after arrival and usually lasts around 2 days, although in some cases the problem may persist for 2 weeks or more. TD is often self-limiting, however, in 2-10% of the cases it may lead to persistent complaints and in 4-31% of the cases even to post-infections3.
TD is most often caused by intestinal overgrowth of the pathogenic enterotoxigenic E. coli (ETEC). Other bacteria known to be the possible cause of TD are Campylobacter jejuni, Shigella species and Salmonella species4,5.
In general, TD prevention consists of the following advice: ‘Boil it, peel it, cook it or forget it.’ However, compliance with dietary precautionary measures is poor and it has been shown that education on food and liquid consumption in foreign countries does not reduce the incidence of diarrhoea6. Another option is to administer preventive antibiotics. However, this always involves side-effects, as well as the possibility of antibiotic resistance and disturbances of the normal intestinal microbiota2.
Winclove Travel is a multispecies probiotic developed to prevent intestinal microbiota disturbances and hereby reduces the risk of traveller’s diarrhoea.
The bacterial strains in Winclove Travel have been selected for their capacity to inhibit pathogens known to cause TD, such as; E. coli, Shigella and Salmonella.
Bacterial strains in Winclove Travel:
B. bifidum W23
L. acidophilus W37
L. casei W56
L. plantarum W62
L. rhamnosus W71
L. salivarius W24
Lc. lactis W58
Previous study results
Winclove Travel has been tested in a pilot study with 200 travelers travelling to high-risk areas. The travelers took 5 grams of Winclove Travel once daily, starting a couple of days before their trip. With the end of the trip all travelers filled out a diary during their trip, scoring their defecation pattern according to the Bristol stool scale. Results show that Winclove Travel is able to reduce the risk of TD. Only 19% developed TD, which is normally 40%. Of the participants 42% stated to have benefited from the product.
Results from 200 travellers taking Winclove Travel
A new scientific publication is expected with Winclove Travel on protection against potential pathogens. The publication has been accepted by Gut Pathogens for publication. This new research has been carried in collaboration with researchers from the University of Urbino “Carlo Bo”, Urbino, Italy. Department of Biomolecular Science, Division of Toxicological, Hygiene and Environmental Sciences.
We will keep you updated about the publication.
1 Steffan R. Epidemiology of Traveler’s Diarrhea. Clin. Infect. Diseases. 2005; 41:S536-40.
2 Shah N. et al. Global etiology of travelers’ diarrhea: systematic review from 1973 to the present. Am J Trop Med Hyg. 2009:80(4);609-614.
3 DuPont H.l. et al. A Randomized, Double-Blind, Placebo- Controlled Trial of Rifaximin To Prevent Travelers’ Diarrhea. Ann intern Med 2005;142(10):805-812
4 DuPont H.L. Systematic review: the epidemiology and clinical features of travellers’ diarrhoea. Aliment Pharmacol Ther. 2009;30(3):187-196.
5 Mulder L. Probiotics in the prevention of traveller’s diarrhoea. Agrofood. 2004;March/April:43-44.
6 Cavalcanti A et al. Traveler’s diarrhea: epidemiology and impact on visitors to Fortaleze, Brazil. Rev Panam Salud Publica. 2002;11(4);245-252.
Klik op het menu voor inhoud en andere functies.
Gebruik de pijlen aan de zijkant om door het magazine te bladeren.